<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03349801</url>
  </required_header>
  <id_info>
    <org_study_id>ECR-AMD-2017-13</org_study_id>
    <secondary_id>MACUSTAR</secondary_id>
    <nct_id>NCT03349801</nct_id>
  </id_info>
  <brief_title>Development of Novel Clinical Endpoints in Intermediate AMD</brief_title>
  <acronym>MACUSTAR</acronym>
  <official_title>Development of Novel Clinical Endpoints for Interventional Clinical Trials With a Regulatory and Patient Access Intention in Patients With Intermediate Age-related Macular Degeneration (AMD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Frank G. Holz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Moorfields Eye Hospital NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Association for Innovation and Biomedical Research on Light and Image</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>City, University of London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Clinical Research Infrastructure Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>La Fondation Voir et Entendre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Sheffield</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Carl Zeiss Meditec AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Innovative Medicines Initiative</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Bonn</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Development of novel clinical endpoints for interventional clinical trials with a regulatory&#xD;
      and patient access intention in patients with intermediate age-related macular degeneration&#xD;
      (AMD) - MACUSTAR&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the MACUSTAR clinical study is to develop novel clinical endpoints for&#xD;
      clinical trials with a regulatory and patient access intention in patients with intermediate&#xD;
      age-related macular degeneration (iAMD). Additional objectives are to characterize the visual&#xD;
      impairment in iAMD and its progression, as well as identify risk factors for progression to&#xD;
      late stage AMD.&#xD;
&#xD;
      Moreover, MACUSTAR aims to optimize and standardize most relevant existing and/or rapidly&#xD;
      available clinical endpoints in:&#xD;
&#xD;
        -  visual functional outcomes measures&#xD;
&#xD;
        -  structural outcomes measures&#xD;
&#xD;
        -  patient reported outcomes measures (PROMs)&#xD;
&#xD;
      The study will be composed by two parts:&#xD;
&#xD;
        -  a cross-sectional part to technically evaluate the functional and structural outcome&#xD;
           measures to support a biomarker qualification by regulatory authorities and payers; and&#xD;
&#xD;
        -  a longitudinal part to assess the prognostic power of changes in retinal sensitivity (as&#xD;
           measured by microperimetry) for progression from iAMD to late AMD (nAMD and GA).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 26, 2018</start_date>
  <completion_date type="Anticipated">November 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change from baseline in best corrected visual acuity (BCVA) using an early treatment diabetic retinopathy study (ETDRS) chart</measure>
    <time_frame>3 years from baseline</time_frame>
    <description>standard parameter, tested for comparison (reference variable)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change from baseline in scotopic and mesopic microperimetry sensitivity</measure>
    <time_frame>3 years from baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change from baseline in low luminance visual acuity (LLVA)</measure>
    <time_frame>3 years from baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change from baseline in vanishing optotypes visual acuity (VA)</measure>
    <time_frame>3 years from baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change from baseline in low luminance deficit (LLD)</measure>
    <time_frame>3 years from baseline</time_frame>
    <description>LLD = BCVA-LLVA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change from baseline in absolute rod threshold of the dark adaptation test</measure>
    <time_frame>3 years from baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change from baseline in rod intercept time of the dark adaptation test</measure>
    <time_frame>3 years from baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects with progression in dark adaptation deficit beyond coefficient of repeatability structural</measure>
    <time_frame>3 years from baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change from baseline in the cube root of drusen volume by spectral-domain optical coherence tomography (SD-OCT)</measure>
    <time_frame>3 years from baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change from baseline in retinal thickness by spectral-domain optical coherence tomography (SD-OCT)</measure>
    <time_frame>3 years from baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Focal pigmentary changes captured by colour fundus photography (CFP)</measure>
    <time_frame>3 years from baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Presence of refractile deposits</measure>
    <time_frame>3 years from baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Presence of intraretinal cystoid spaces</measure>
    <time_frame>3 years from baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Presence of localized retinal pigment epithelium (RPE) hypertransmission</measure>
    <time_frame>3 years from baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Presence of localized disruption of ellipsoid zone</measure>
    <time_frame>3 years from baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Presence of localized subsidence of the outer plexiform layer and the inner nuclear layer</measure>
    <time_frame>3 years from baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Presence of hyporeflective wedge-shaped bands</measure>
    <time_frame>3 years from baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Presence of reticular drusen/subretinal drusenoid deposits and associated local changes as determined by multimodal imaging</measure>
    <time_frame>3 years from baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in localized fundus autofluorescence signal alterations</measure>
    <time_frame>3 years from baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects with reduction in drusen volume</measure>
    <time_frame>3 years from baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects with study eye that progressed to geogrphic atrophy (GA) and/or neovascular age-related macular degeneration (nAMD)</measure>
    <time_frame>3 years from baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects with conversions to late AMD detected with fluorescein angiography (FA) that could be detected with OCT-A (at equipped sites)</measure>
    <time_frame>3 years from baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Presence of quiescent choroidal neovascularisation (CNV) as assessed by optical coherence tomography angiography (OCT-A) (at equipped sites)</measure>
    <time_frame>3 years from baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>OCT-A findings (at equipped sites)</measure>
    <time_frame>3 years from baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change from baseline in patient-reported low luminance visual functioning, as measured by the vision impairment in low luminance (VILL) questionnaire, including the domains of reading &amp; accessing information</measure>
    <time_frame>3 years from baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change from baseline in patient-reported low luminance visual functioning, as measured by the VILL questionnaire, including the domains of Orientation &amp; mobility (incl. driving)</measure>
    <time_frame>3 years from baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change from baseline in patient-reported low luminance visual functioning, as measured by the VILL questionnaire, including the domains of safety</measure>
    <time_frame>3 years from baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change from baseline in patient-reported low luminance visual functioning, as measured by the VILL questionnaire, including the domains of socio-emotional well-being</measure>
    <time_frame>3 years from baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in utility index from baseline as measure by the patient-reported outcome measure (PROM) utility index</measure>
    <time_frame>3 years from baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change from baseline in patient-reported health status and utility using the EQ-5D-5L questionnaire (EuroQol Group)</measure>
    <time_frame>3 years from baseline</time_frame>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">718</enrollment>
  <condition>Age Related Macular Degeneration (AMD)</condition>
  <arm_group>
    <arm_group_label>no AMD</arm_group_label>
    <description>No interventions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>early AMD</arm_group_label>
    <description>No interventions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intermediate AMD</arm_group_label>
    <description>No interventions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>late AMD</arm_group_label>
    <description>No interventions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>According to clinical practice.</description>
    <arm_group_label>early AMD</arm_group_label>
    <arm_group_label>intermediate AMD</arm_group_label>
    <arm_group_label>late AMD</arm_group_label>
    <arm_group_label>no AMD</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples are collected in the study for two purposes: biobanking and genetic analysis.&#xD;
      Detailed instructions on processing and storage of blood samples are provided in a specific&#xD;
      manual that will be provided to the clinical sites. Blood samples are stored in a&#xD;
      pseudonimysed form.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study will include subjects with no AMD or normal aging changes and subjects with AMD&#xD;
        classified in accordance with the international Beckman Classification.&#xD;
&#xD;
        A total of 750 subjects will be recruited:&#xD;
&#xD;
          -  300 subjects will participate in the Cross-sectional part:&#xD;
&#xD;
               -  50 with normal aging changes, no AMD&#xD;
&#xD;
               -  50 with early AMD,&#xD;
&#xD;
               -  50 with late AMD&#xD;
&#xD;
               -  150 with iAMD&#xD;
&#xD;
          -  650 subjects will participate in the longitudinal part:&#xD;
&#xD;
               -  600 iAMD&#xD;
&#xD;
               -  50 early AMD&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        General Inclusion criteria (applicable to all groups)&#xD;
&#xD;
          1. Male and female subjects.&#xD;
&#xD;
          2. Aged 55 - 85 years at baseline.&#xD;
&#xD;
          3. Able and willing to provide written informed consent and to comply with the study&#xD;
             protocol visits and assessments.&#xD;
&#xD;
        Intermediate AMD&#xD;
&#xD;
          1. Study eye must have iAMD and,&#xD;
&#xD;
          2. The fellow eye must have iAMD and/or, in addition, extrafoveal GA (no atrophy within&#xD;
             the central ETDRS subfield), maximum total GA size is 1.25 mm2.&#xD;
&#xD;
          3. ETDRS letter chart BCVA in the study eye not worse than 72 letters (approximately&#xD;
             20/40 Snellen VA equivalent).&#xD;
&#xD;
          4. All general inclusion criteria.&#xD;
&#xD;
        Late AMD&#xD;
&#xD;
          1. Subjects with bilateral GA, bilateral nAMD or nAMD in one eye and GA in the other.&#xD;
&#xD;
          2. BCVA between 20/80 and 20/200 in study eye.&#xD;
&#xD;
          3. All general inclusion criteria.&#xD;
&#xD;
        Early AMD&#xD;
&#xD;
          1. Subjects with medium drusen &gt; 63μm and ≤ 125μm and no AMD pigmentary abnormalities in&#xD;
             both eyes and not signs of intermediate or late AMD.&#xD;
&#xD;
          2. All general inclusion criteria.&#xD;
&#xD;
        No AMD&#xD;
&#xD;
          1. No signs of early, intermediate or late AMD in both eyes.&#xD;
&#xD;
          2. All general inclusion criteria only.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        General Exclusion criteria (applicable to all groups)&#xD;
&#xD;
          1. Media opacity or eye movement disorder (nystagmus) that interferes with retinal&#xD;
             imaging data quality in the opinion of the investigator.&#xD;
&#xD;
          2. Severe ptosis, extraocular motility restriction or head tremor preventing adequate&#xD;
             fundus visualization in the opinion of the investigator.&#xD;
&#xD;
          3. Any signs of nAMD or GA (does not apply to the late AMD group).&#xD;
&#xD;
          4. Any concurrent intraocular condition in the study eye (e. g. glaucoma or cataract)&#xD;
             that, in the opinion of the investigator would either require surgical intervention&#xD;
             during the study to prevent or treat visual loss that might result from that condition&#xD;
             or affect interpretation of study results.&#xD;
&#xD;
          5. Severe non-proliferative diabetic retinopathy, or proliferative diabetic retinopathy.&#xD;
&#xD;
          6. Any diabetic macular edema or macular disease&#xD;
&#xD;
          7. Ocular disorders in the study eye (i. e., pre-retinal membrane) at the time of&#xD;
             enrolment that may confound interpretation of study results and compromise visual&#xD;
             acuity.&#xD;
&#xD;
          8. Diagnosis of uncontrolled glaucoma with intraocular pressure of &gt;30 mmHg (despite&#xD;
             current pharmacological or non-pharmacological treatment).&#xD;
&#xD;
          9. Known systemic illness which in the opinion of the investigator will prevent from&#xD;
             actively participating in the study.&#xD;
&#xD;
         10. Concomitant treatment for AMD in either eye (concomitant use of vitamins/supplements&#xD;
             is not excluded; does not apply to the late AMD group).&#xD;
&#xD;
         11. Any periocular or intravitreal injections (IVT) in either eye (does not apply to the&#xD;
             late AMD group).&#xD;
&#xD;
         12. Participation in any other interventional trial.&#xD;
&#xD;
         13. Obvious retinal changes due to causes other than AMD (e.g. evidenced by an existing&#xD;
             diagnosis of monogenetic macular dystrophies, Stargardt disease, cone rod dystrophy,&#xD;
             or toxic maculopathies).&#xD;
&#xD;
         14. Any history of allergies to fluorescein.&#xD;
&#xD;
        Intermediate AMD&#xD;
&#xD;
          1. Any GA in the study eye&#xD;
&#xD;
          2. Any extrafoveal GA larger than 1.25 mm2 in the fellow eye.&#xD;
&#xD;
          3. All general exclusion criteria.&#xD;
&#xD;
        Late AMD&#xD;
&#xD;
        1. All general exclusion criteria only.&#xD;
&#xD;
        Early AMD&#xD;
&#xD;
          1. Intermediate or late AMD (following Beckman classification) in any eye.&#xD;
&#xD;
          2. All general exclusion criteria.&#xD;
&#xD;
        No AMD&#xD;
&#xD;
          1. Early to late AMD (following Beckman classification) in any eye.&#xD;
&#xD;
          2. All general exclusion criteria.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank Holz, Prof. Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bonn</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Righospitalet Copenhagen</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal de Creteil</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre d'Investigation Clinique Centre National d'Ophtalmologie des Quinze-Vingts</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Bonn</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Cologne</name>
      <address>
        <city>Cologne</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Ophthalmology, University of Freiburg</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Eye Hospital Munich</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Franziskus Hospital</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universtiy Hospital Tuebingen</name>
      <address>
        <city>Tübingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Eye Hospital Ulm</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Luigi Sacco Hospital</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>G.B.Bietti Eye Foundation</name>
      <address>
        <city>Rom</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radboud University Medical Centre</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radboud University Medical Centre</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre for Clinical Trials, AIBILI</name>
      <address>
        <city>Coimbra</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar de São João, E.P.E.</name>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen's University Belfast</name>
      <address>
        <city>Belfast</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gloucestershire Hospitals NHS Foundation Trust</name>
      <address>
        <city>Gloucester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moorfields Eye Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Portugal</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://macustar.eu</url>
    <description>Related Info</description>
  </link>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 10, 2017</study_first_submitted>
  <study_first_submitted_qc>November 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2017</study_first_posted>
  <last_update_submitted>November 5, 2020</last_update_submitted>
  <last_update_submitted_qc>November 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Bonn</investigator_affiliation>
    <investigator_full_name>Frank G. Holz</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <keyword>iAMD</keyword>
  <keyword>biomarker</keyword>
  <keyword>clinical endpoint</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

